You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase I 2024 Department of EnergyARPA-E -
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase II 2024 Department of EnergyARPA-E -
PREFAB MODULAR LIQUID-COOLED MICRO DATA CENTER
SBC: Flexnode Inc Topic: 1"To enable the future needs of efficient computing for edge data centers, Flexnode and its partners, the University of Maryland (UMD), Boeing, Iceotope, SHoP Architects, and Arup, propose to develop a prefabricated modular micro data center with unprecedented energy efficiency and power density. The proposed system leverages four key component and system-level technology advancements: (a) a novel, ...
STTR Phase II 2024 Department of EnergyARPA-E -
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
SBC: Amplo Biotechnology, Inc. Topic: 106PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Inducible HMGB1 antagonist for viral-induced acute lung injury.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NHLBIFor more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain
SBC: H-CUBED Topic: NIDAKnee Osteoarthritis (KOA) is a degenerative joint disease that leads to significant pain and functional disability affecting over 30% of older adults making it one of the most common and debilitating conditions related to aging. This disease results in a loss of mobility, reduced quality of life, and in ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a portable beat-to-beat fetal ECG system
SBC: AUSCULTECH DX LLC Topic: NICHDProject Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs
SBC: Prometheus Technologies, LLC Topic: NIEHSProject Summary Each year, between 340,000 and 900,000 premature deaths can be linked to air pollution caused by releasing Volatile Organic Compounds (VOCs), i.e., an estimated 1.8 billion tons of VOCs are emitted to the global environment each year. Also, some VOCs cause serious adverse health effects even at the trace level concentration, e.g., cancer, damage to the central nervous and immune sy ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Pigment Sensing Pulse Oximeter Technology for Mitigating Racial Bias in Oxygen Saturation Measurements
SBC: PENDERIA TECHNOLOGIES, INC. Topic: 100Abstract Wearable pulse oximetry sensors are among the most ubiquitous medical technologies used in healthcare. Clinicians rely on pulse oximeters to monitor patient health during disease states and medical procedures. However, numerous studies have shown this technology to be racially biased; hypoxemia is three times more likely to go undetected in patients with dark skin compared to those with l ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An immunotherapeutic IgY formulation against norovirus diarrhea
SBC: SCALED MICROBIOMICS LLC Topic: NIAIDProject Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health